Palliative Emergencies. Ken Stakiw

Similar documents
Dyspnea: The top things you need to you know! Dr. Megan Sellick & Dr. Lawrence Lee Edmonton Zone Palliative Care Program

Management of Dyspnea and Cough in Lung Cancer

Dyspnea. Stephanie Lindsay

PRACTICAL DYSPNEA MANAGEMENT Margot Sondermann BScPT, MEd. Palliative Consultant for End-Stage Lung Disease, Calgary Zone

Dyspnea: Evaluation and Management

Regional Breathlessness Audit - Case Note Survey. 1. Introduction. Regional Breathlessness Audit - Case Note Survey. 2.

Symptom Management and Palliative Care for Lung Cancer

Waterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC)

Palliative Care Emergencies. Additional module if needed

BREATHLESSNESS MANAGEMENT

GUIDELINES & PROTOCOLS

Breathlessness in advanced disease. February 2017

Managing Respiratory Symptoms - Breathlessness, Cough and Secretions. Dr Laura Healy. Palliative Medicine Registrar, Beaumont Hospital.

Management of Dyspnea/Breathlessness for the Medical and Hematological Oncologist

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL

2018 OCN Keywords January 22, 2018 Subject Area Weight Keywords

Jamie Rickards, PharmD, MBA, BCPS, CPP PGY-2 Geriatric Pharmacy Resident

I have no financial disclosures.

Palliative care in long-term conditions Scottish Palliative Care Pharmacists Association

Dr. A. Kerigan BREATHLESSNESS AT THE END OF LIFE

MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life

a. Will not suppress respiratory drive in acute asthma

Approach to symptom control near the end-of-life

Hospice and Palliative Medicine

5/3/2012 PRESENTATION GOALS RESPIRATORY THERAPISTS ROLE IN END OF LIFE CARE FOR THE PULMONARY PATIENT

Respiratory Issues at End-of-Life. Jerry Boltz, FNP January 27, L N E C Geriatric Curriculum

Dyspnea: Should we use BIPAP?

Supportive Care. End of Life Phase

Opioid Pearls and Acute Pain Management

CLINICAL GUIDELINES FOR END OF LIFE CARE MEDICATIONS IN LONG TERM CARE HOMES

PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose

Care in the Last Days of Life

Sam H Ahmedzai Academic Unit of Supportive Care Department of Oncology The University of Sheffield & Sheffield Teaching Hospitals NHS Foundation

This is my lecture about breathing

4/3/2018. Management of Acute Pain Crises. Five Mistakes I ve made and why you shouldn t

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

Symptom Management Guidelines for End of Life Care

Dyspnea: Assessment and Management

APHN. Shortness of breath. Ednin Hamzah CEO, Hospis Malaysia.

Using Evidence Based Medicine to Ethically Provide End of Life Symptom Control

Palliative Care: What is it?

What is the most important information I should know about midazolam?

Jeffrey B. Rubins, MD Director, Palliative Medicine, HCMC Professor of Medicine, UMN

Course Handouts & Disclosure

Palliative care for heart failure patients. Susan Addie

Management of Delirium in Hospice Patients

Intranasal Medications

Multiple Choice Questions

The last days of life in hospital and at home

Pain management. Coleman Palliative Care Conference: February 2016 Josh Baru MD Stacie Levine MD

Symptom Management II:

BJF Acute Pain Team Formulary Group

PAIN MANAGEMENT Patient established on oral morphine or opioid naive.

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety

PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG

10/4/2017. Rationale symptom management. Satisfactory. NCCN Palliative Care Guidelines. Respiratory Symptoms. Dyspnea: Overview and Incidence


The Role of Palliative Care in Advanced Lung Disease

4/10/2018. Rationale symptom management. NCCN Palliative Care Guidelines. Satisfactory. Respiratory Symptoms. Dyspnea: Overview and Incidence

ADMINISTRATIVE POLICY AND PROCEDURE MANUAL. Subject: Moderate Sedation/Analgesia- Procedural ( Conscious Sedation ) Policy

A Visual Approach to Simplifying Respiratory Drug Regimens

RESPIRATORY FAILURE - CAUSES, CLINICAL INFORMATION, TREATMENT AND CODING CONVENTIONS

A Visual Approach to Simplifying Respiratory Drug Regimens

Symptom Control in the Community Setting. Dr Andrew Tysoe-Calnon

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.

COPD - Palliation. Dr Tamara Holling MD, CCFP, focussed practice in Geriatric Medicine

Opioid Pain Management. John Manfredonia, DO. Disclosures. Dr. Manfredonia discloses his employment as Regional Medical Director for VistaCare

some things you should know about opioids before starting a prescription an informational booklet for opioid pain treatment

Palliative Sedation An ICU Perspective. William Anderson; B.Sc. MD FRCP(C) Department of Critical Care Thunder Bay Regional HSC

PAIN MANAGEMENT Person established taking oral morphine or opioid naive.

Tracy Ward Highly Specialist Respiratory Nurse Rotherham NHS Foundation Trust

Goals for sedation during mechanical ventilation

Dyspnea in the Cancer Patient 33 rd Annual PSONS Nursing Symposium April 1, 2011

The Quebec Palliative Sedation Guidelines. Rose DeAngelis, N, MSc(A), CHPCN (C)

Symptom Management Challenges at End-of-Life

Palliative Care Out-of-hours. A resource pack for West Dorset. Contents:

Managing Care at End of Life:

Non Pharmacological Breathlessness and Fatigue Management

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT

Title: Pharmacological Management for Dyspnea in Palliative Cancer Patients: Clinical Review and Guidelines

1/3/2008. Karen Burke Priscilla LeMone Elaine Mohn-Brown. Medical-Surgical Nursing Care, 2e Karen Burke, Priscilla LeMone, and Elaine Mohn-Brown

In our patients the cause of seizures can be broadly divided into structural and systemic causes.

Chapter 11: Respiratory Emergencies

Medications used for symptom control in palliative care

10/17/16. Acute Respiratory Failure in the Acute Care Setting. Margaret Rosales, APRN-CNP, FNP

MICHIGAN. Table of Contents. State Protocols. Adult Treatment Protocols

1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER

Pain Management in Hospice and Palliative Care

Chapter 15. Seizures. Learning Objectives. Learning Objectives 9/11/2012

Symptom Management Pocket Guides: DELIRIUM

Pediatric Procedural Sedation

Syringe driver in Palliative Care

Lorazepam and meclizine

Hospice and Palliative Nurses Association (HPNA) Clinical Practice Forum October 23 24, 2015

Palliative Care and the Pulmonary Patient. DorAnne Donesky, PhD, ANP-BC, ACHPN Dept of Physiological Nursing

Palliative Care and the Critical Role of the Pharmacist. Arti Thakerar Education/ Palliative Care Peter MacCallum Cancer Centre

Pain in the Pediatric Palliative Care Context

Pulmonary Pathophysiology

Infectious: (including pericarditis, pleurisy, pneumonia) atypical mycobacterium (MAC) CMV fungi. herpes zoster

ANSWER # 1 PHARMACOLOGY. Methadone answers Stoltzfus 4/5/2012 METHADONE: WHY GRANDMA S TAKING A DIPHENYLHEPTANE (ANSWERS) JANUARY 26, 2017

Transcription:

Palliative Emergencies Ken Stakiw

Disclosure None to disclose for this lecture Have received honoraria from a number of agencies and companies previously Intend to discuss some off label use of medications I will indicate personal approaches and experiences

Palliative Emergency In most medical specialties emergencies are those situations which if left untreated will immediately threaten life. In Palliative Care where death is often an expected outcome emergencies are those conditions which if left untreated will seriously threaten the quality of life

Palliative Emergencies Seizures Pain Crises Acute Dyspnea Spinal Cord Compression Hypercalcemia Superior Vena Cava Obstruction Haemorrhage

Seizures Objectives To assess and manage seizures including Status Epilepticus

P.H. 58 yr. old with metastatic Prostate cancer Admitted to hospital with weakness, severe pain, and trouble with vision esp. L eye associated with L sided facial weakness Mets. to many bones

P.H. Had hormonal resistant prostate cancer and chose not to have any further therapy except comfort measures Initial therapy targetted to pain control

P.H. Admitted Nov. 15 Nov. 25 had generalized seizure Versed 5 mg. s.c. seizure activity stopped but he remained very agitated Versed 2 mg. repeated q 5 min. until agitated behaviour stopped total of 8 mg.

P.H. Dilantin 300 mg po initiated Serum blood levels monitored dose increased to 500 mg. od Nov. 30 further seizure managed with versed 5 mg. s.c. Therapeutic levels of Dilantin could not be achieved in spite of increase to 700 mg./day

P.H. No further seizures but switched to Keppra Gradual deterioration died Jan.9

Seizures Generalized usually with loss of consciousness Partial may also be associated with loss of consciousness Status Epilepticus Persistant Seizure activity for 30 min. or recurrent seizures without regaining consciousness

SeizureTreatment Usually in bed if not recovery position (once seizure is over) remove objects that may injure

Seizure Treatment Medications Midazolam (Versed) 2.5-5 mg. s.c. may be repeated q 5 min. until seizure stops May also be continued intermittently or by continuous infusion if necessary Lorazepam (Ativan) 2 mg. s.c. or i.v. repeat in 10 min. Diazepam (Valium) rectal solution 10mg.

Status Epilepticus Midazolam (Versed) for Continuous Seizure after 2 doses of 5 mg. - 5 min. apart 10 mg. s.c. then continuous s.c. infusion beginning at 1 mg./hour increasing by 1 mg./hr. (may need repeat Versed bolus of 5-10 mg. If possible start i.v. for drug administration

Pain Crises Objective To assess and manage pain crises

R.O. 67 year old male Metastatic colon cancer to bones, liver, and lungs Severe pain in pelvic bones and R ribs Seen as outpatient and had his opioids titrated to manage pain

R.O. Admitted to hospital some time later with very severe pain 10/10 mainly back Meds - Hydromorph contin 60 mg. bid and hydromorph 8 mg. q1h prn (took 8 doses per day previous 3 days) now in addition to pain has nausea, vomiting, and confusion What do you do?

Pain Crises Cause? Review med list PIP Family Pharmacist Nurse

Pain Crises Management Stacking Single Double

Remember Parenteral (injectable) 2X the strength of oral route i.e. injectable dose = oral dose divided by 2

Tmax Tmax after PO (approx.) 1 hr. SC, IM (approx.) 30 min. IV (approx.) 6 min.

Practicality When using immediate release preparations for breakthrough pain Orally dose q1h S.c. dose q30 min. I.v. dose q 6-10 min.

R.O. Issue pain crisis needs immediate attention 184 mg. po = 92 mg. s.c. / i.v. Usual breakthrough dose is 10% of daily dose 9 mg.

R.O. Single Stacking 8 mg. s.c. q 30 min. 8 mg. i. v. q10-15 min. Double Stacking 8 mg. s.c. start 16 mg. in 30 min. 8 mg. i.v. start 16 mg. in 10 15 min.

Acute Titration Can redose at Tmax if pain persists If pain moderate to severe could increase dose by 50 100% Pain is usually controlled within 2-3 doses

Acute Dyspnea Assess and manage acute dyspnea

N.W. 78 year old F diagnosed with lung cancer 2010 Non operable managed with chemo. and radiation (chemo caused severe nausea and vomiting so d/c) Noted to have recurrence 2011 one further attempt with chemo Tarceva but ineffective

N.W. Presented to hospital with severe dyspnea

N.W. Current med. at home hydromorph contin 9 mg. bid Hydromorph 2 mg. q1h prn for breakthrough

N.W. Mottled cyanotic obviously gasping and very frightened How long do I have

N.W. Started on hydromorph 0.5 mg. s.c. and Versed 0.25 mg. q4h with the same dose q1h prn

N.W. The next day sitting up eating and talking

Dyspnea The awareness of uncomfortable breathing Complex Subjective Symptom May be influenced by psychosocial and spiritual factors

Dyspnea Patient s assessment of their dyspnea is most reliable Clinical signs don t always correlate with the respiratory experience Not necessarily related to resp. rate nor O2 sat.

Dyspnea - causes Pulmonary Airway obstruction, pleural effusion, COPD, Lymphangitic carcinomatosis, pneumonia, pulmonary embolism Cardiac CHF, Pericardial effusion Systemic causes Anemia

Dyspnea causes Muscle weakness ALS, Cachexia Other Ascites Psychological

Dyspnea management Identify and treat underlying causes if possible Treat Symptom Always communicate with family and patient

Dyspnea management Non pharmacological Avoid exacerbaton activities and conserve energy Normalize emotional responses Fan Position: lean foreward, head up Limit people in room Reduce temperature and humidity

Non pharmacological Open window and allow to see outside Avoid irritants e.g. smoke strong scents Relaxation therapy

Oxygen in Dyspnea In hypoxemic patients oxygen improves tissue hypoxia reducing ventilatory drive, pulmonary vascular resistance and peripheral vascular resistance Oxygen is often recommended for dyspnea When PaO>55 results conflicting

Oxygen International randomized controlled trial Oxygen vs. medical air Results: Palliative Oxygen does not appear to confer any additional benefit over medical air for relieving dyspnea or improving quality of life

Pharmacological Morphine backed by evidence Safe and effective Opioid naïve 5 mg. q6h p.o. or 2.5 mg. s.c. Q6h May use long acting Nebulized no systemic benefit

Pharmacological Other opioids - no randomized data but anectodal effectiveness

Pharmacological Inhaled furosemide Studies show symptomatic benefit for 1-4 hrs.

Pharmacological Benzodiazepines Recent study compared morphine to midazolam- also used in combination Combo provided greatest relief Morphine and midazolam equally effective

Pharmacological Psychotropic drugs useful as anxiety plays large role Methotrimeprazine 5-10 mg. b-tid Steroids Bronchodilators

Pharmacological Triple neb. Mix Morphine (inj.) 5 mg. Decadron (inj.) 4 mg. Salbutamol (neb.) 2.5 mg. nebulized q 2-3 h. prn Oral rinse with water following Effective anecdotally for dypnea and cough